Concept Life Sciences is a knowledge and science-led contract research organisation (CRO) with a proven track record in life sciences, laboratory based analytical testing and specialist consulting.
We have a team of 250 scientists, across our specialist therapeutic areas (Oncology, Immunology & Neuroscience), many of whom have > 25 years’ experience in:
- Drug Discovery
- ADMET & DMPK
- Bioanalysis and Biomarkers
- Safety and Toxicology
- Specialist Histology
- GMP & Manufacturing
- Food/Feed Testing
Our company has grown and evolved through acquisition of key industry CRO’s. Our strengths of specialism now provide integrated or focused stand-alone drug discovery and development services globally.
In 2017, Concept Life Sciences acquired Aquila BioMedical. This acquisition represented a pivotal addition to the comprehensive range of services Concept provides, supporting customers throughout their drug discovery and development processes.
In January 2018, Concept Life Sciences became an Operating Company of Spectris plc.